Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Aditxt stock | $2.81

Learn how to easily invest in Aditxt stock.

Aditxt, Inc
NASDAQ: ADTX - USD
BIOTECHNOLOGY
$2.14
-$0.09 (-4.04%)

Aditxt, Inc is a biotechnology business based in the US. Aditxt shares (ADTX) are listed on the NASDAQ and all prices are listed in US Dollars. Aditxt employs 43 staff and has a market cap (total outstanding shares value) of 0.00.

How to buy shares in Aditxt

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – ADTX – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Aditxt stock price (NASDAQ: ADTX)

Use our graph to track the performance of ADTX stocks over time.

Aditxt shares at a glance

Information last updated 2021-07-28.
Latest market close$2.81
52-week range$1.66 - $9.58
50-day moving average $2.60
200-day moving average $2.89
Wall St. target price$14.00
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-0.60

Buy Aditxt shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
Stocks, ETFs, Cryptocurrency
N/A
0%
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Webull
Stocks, Options, ETFs
$0
0%
Get one free stock valued between $3.00 and $300 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Public
Stocks, ETFs
N/A
$0 per month
Download and sign up with Public.com; approved accounts receive a free stock slice worth up to $70, selected from 9 popular stocks.
Open an account
Commission-free trading in stocks and ETFs with a social networking twist.
J.P. Morgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract
0%
N/A
INVESTMENT AND INSURANCE PRODUCTS ARE: NOT A DEPOSIT • NOT FDIC INSURED • NO BANK GUARANTEE • MAY LOSE VALUE
Robinhood
Stocks, Options, ETFs
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Moomoo
Stocks, Options, ETFs
$0
$0 per year
N/A
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Aditxt stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Aditxt price performance over time

Historical closes compared with the close of $2.81 from 2021-05-28

1 week (2021-07-22) N/A
1 month (2021-07-02) 7.66%
3 months (2021-04-30) -1.75%
6 months (2021-01-29) N/A
1 year (2020-07-29) N/A
2 years (2019-07-29) N/A
3 years (2018-07-29) N/A
5 years (2016-07-29) N/A

Aditxt financials

Gross profit TTM $0
Return on assets TTM -95.4%
Return on equity TTM -365.54%
Profit margin 0%
Book value $0.79
Market capitalisation $31.9 million

TTM: trailing 12 months

Shorting Aditxt shares

There are currently 510,047 Aditxt shares held short by investors – that's known as Aditxt's "short interest". This figure is 4.4% down from 533,715 last month.

There are a few different ways that this level of interest in shorting Aditxt shares can be evaluated.

Aditxt's "short interest ratio" (SIR)

Aditxt's "short interest ratio" (SIR) is the quantity of Aditxt shares currently shorted divided by the average quantity of Aditxt shares traded daily (recently around 100009.21568627). Aditxt's SIR currently stands at 5.1. In other words for every 100,000 Aditxt shares traded daily on the market, roughly 5100 shares are currently held short.

However Aditxt's short interest can also be evaluated against the total number of Aditxt shares, or, against the total number of tradable Aditxt shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Aditxt's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Aditxt shares in existence, roughly 30 shares are currently held short) or 0.0466% of the tradable shares (for every 100,000 tradable Aditxt shares, roughly 47 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Aditxt.

Find out more about how you can short Aditxt stock.

Aditxt share dividends

We're not expecting Aditxt to pay a dividend over the next 12 months.

Aditxt overview

ADiTx Therapeutics, Inc. , a biotech company, develops technologies focuses on improving the health of the immune system through immune reprogramming and monitoring. It develops AditxtScore that allows individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its own tissues. The company is also developing ADi products for organ transplantation, including skin grafting, autoimmune diseases, and allergies. ADiTx Therapeutics has a license agreement with Loma Linda University and Leland Stanford Junior University. ADiTx Therapeutics, Inc. was incorporated in 2017 and is headquartered in Mountain View, California.

Stocks similar to Aditxt

Frequently asked questions

What percentage of Aditxt is owned by insiders or institutions?
Currently 15.159% of Aditxt shares are held by insiders and 8.115% by institutions.
How many people work for Aditxt?
Latest data suggests 43 work at Aditxt.
When does the fiscal year end for Aditxt?
Aditxt's fiscal year ends in December.
Where is Aditxt based?
Aditxt's address is: 737 N. Fifth Street, Richmond, VA, United States, 23219
What is Aditxt's ISIN number?
Aditxt's international securities identification number is: US0070251097

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site